Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADMA BIOLOGICS, INC.ADMA · Entity 4477 | Director | February 26, 2024 | February 29, 2024 |
| TruGolf Holdings, Inc.DMAQU · Entity 8632 | Director | October 26, 2021 | October 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADMA BIOLOGICS, INC.
Report date February 26, 2024 · Filed February 29, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 83,941 |
Reported balance
After 2024-02-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-02-26 · Grant · Acquired 24,040 · Balance 83,941 F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 34,086 shares of common stock owned by the reporting person. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.40 · Expires 2034-02-26 | Direct | 37,541 |
Reported balance
After 2024-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-02-26 · Grant · Acquired 37,541 · Balance 37,541 F3: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
F2: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 34,086 shares of common stock owned by the reporting person.
F3: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.
TruGolf Holdings, Inc.
Report date October 26, 2021 · Filed October 26, 2021
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Neos Therapeutics, Inc.
Report date March 19, 2021 · Filed March 19, 2021
Section 16 reporting ended · disclosed 2021-03-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 1
1 source rowRow 1 · 2021-03-19 · Disposition to issuer · Disposed 24,953 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.63 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-03-19 · Disposition to issuer · Disposed 14,777 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-03-19 · Disposition to issuer · Disposed 18,322 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.05 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-03-19 · Disposition to issuer · Disposed 22,756 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.44 | Direct | 0 |
Reported balance
After 2021-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-03-19 · Disposition to issuer · Disposed 46,907 · Balance 0 F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time").
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement).
F3: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock.
F4: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 37,541 | $0.00 Strike: $5.40 | $0.00 |
DisclosureSEC source: 0001140361-24-010238 · form4.xml · derivative · entry 2 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,541 Underlying: Common Stock · 37,541 shares Expires 2034-02-26 F3 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 26, 2024 Filed Feb 29, 2024 02:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 24,040 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-010238 · form4.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,941 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 34,086 shares of common stock owned by the reporting person. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 00:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | SaleCommon Stock | 1,433,304 | $3.87 | $5,544,736.52 |
DisclosureSEC source: 0001140361-23-041054 · form4.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · price: Reflects the weighted average price of sales on August 22, 2023. The shares were sold in multiple transactions at prices ranging from $3.81 to $3.99, inclusive. F2 · ownership.nature: Represents shares sold by Biomark Capital Fund ("Biomark Capital"). Mr. Fong is a Managing Director and General Partner at Biomark Capital and may have been deemed the beneficial owner of such shares. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 51,630 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0001140361-23-010767 · form4.xml · derivative · entry 3 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,630 Underlying: Common Stock · 51,630 shares Expires 2033-03-06 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 02:30 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 25,815 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-010767 · form4.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,901 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes, as of the transaction date, (i) 25,815 RSUs granted on March 6, 2023 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 13,293 RSUs granted on March 7, 2022, which will vest in full on March 7, 2023; and (iii) 20,793 shares of common stock owned by the reporting person. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 53,172 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001140361-22-008674 · form4.xml · derivative · entry 3 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,172 Underlying: Common Stock · 53,172 shares Expires 2032-03-07 F4 · derivative.exercise_date: The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 22:58 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 26,586 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-008674 · form4.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,086 F1 · shares: These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date. F2 · balance_after: Includes (i) 26,586 RSUs granted on March 7, 2022 and reported on this Form 4, subject to vesting as set forth in footnote (1); and (ii) 7,500 shares of common stock owned by the reporting person. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerStock Option (Right to Buy) · Derivative | 46,907 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · derivative · entry 6 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,907 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerStock Option (Right to Buy) · Derivative | 22,756 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · derivative · entry 5 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,756 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,322 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · derivative · entry 4 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,322 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerStock Option (Right to Buy) · Derivative | 14,777 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · derivative · entry 3 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,777 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $15.00 | $0.00 |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · derivative · entry 2 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires not disclosed F4 · kind: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.exercise_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. F4 · derivative.expiration_date: At the Effective Time, each option to purchase Shares of the Company that was outstanding immediately prior to the Effective Time that had an exercise price per share equal to or less than $0.95 (any such option, an "Assumed Company Option") ceased to represent a right to acquire Shares, was assumed by Parent and automatically converted into the option to purchase shares of Parent Common Stock equal to the number of Shares underlying each such Assumed Company Option multiplied by the Exchange Ratio. All outstanding stock options of the Company that were not Assumed Company Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| March 19, 2021 Filed Mar 19, 2021 17:32 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | Disposition to issuerCommon Stock | 24,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-039224 · tm219870-9_4seq1.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · kind: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). F3 · shares: This number includes 23,453 restricted stock units (each, an "RSU") held by the Reporting Person. At the Effective Time, each RSU that was outstanding prior to the Effective Time immediately and automatically ceased to represent a right to acquire shares of Company Common Stock and was assumed by Parent and converted automatically into a restricted stock unit denominated in Parent Common Stock equal to the number of Shares subject to the RSU prior to the Effective Time multiplied by the Exchange Ratio, and any cash in lieu of fractional shares of Parent Common Stock. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement") dated as of December 10, 2020, by and among the Company, Aytu BioScience, Inc. ("Parent"), and Neutron Acquisition Sub, Inc., a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Company (the "Merger") effective as of March 19, 2021 (the "Effective Time"). F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") (excluding any Shares held in the treasury of the Company or owned, directly or indirectly, by Parent or Merger Sub immediately prior to the Effective Time) was cancelled and converted into the right to receive 0.1088 (the "Exchange Ratio") shares of Common Stock of Parent (the "Parent Common Stock"), plus the right, if any, to receive cash in lieu of fractional shares of Parent Common Stock into which such Shares would have been converted (as described in the Merger Agreement). Read SEC document |
| February 25, 2021 Filed Mar 2, 2021 02:03 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $2.35 | $0.00 |
DisclosureSEC source: 0001193805-21-000296 · e620331_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The options vest in twelve equal monthly installments, becoming fully vested on February 25, 2022. Read SEC document |
| June 10, 2020 Filed Jun 11, 2020 20:21 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantCommon Stock | 23,453 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-072544 · a4.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,953 F1 · security: Represents shares of common stock underlying restricted stock unit grants awarded to the Reporting Person. The restricted stock units will vest on the one-year anniversary of June 10, 2020. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:12 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001193805-20-000293 · e619427_4-fong.xml · derivative · entry 2 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-02-28 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Mar 4, 2020 00:12 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000293 · e619427_4-fong.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: These shares represent restricted stock units ("RSUs"), which will vest in equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F1 · balance_after: These shares represent restricted stock units ("RSUs"), which will vest in equal monthly installments, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| February 28, 2020 Filed May 1, 2020 21:10 UTC Amendment | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193805-20-000549 · e619594_4a-fong.xml · nonDerivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 F1 · shares: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. F1 · balance_after: These shares represent restricted stock units ("RSUs"). Subsequent to the filing of the initial Form 4 by the Reporting Person on March 3, 2020, the Board of Directors of the Issuer corrected the vesting schedule of the RSUs. The RSUs will vest in two equal installments, on the six- and 12-month anniversaries of the grant, becoming fully vested on the one-year anniversary of the grant, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 17:33 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 46,907 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001104659-19-035980 · a4.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,907 Underlying: Common Stock · 46,907 shares Expires 2029-06-13 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which began on June 13, 2019. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 21:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $3.89 | $0.00 |
DisclosureSEC source: 0001193805-19-000292 · e618301_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-03-13 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) March 13, 2029 and (ii) the one-year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| July 02, 2018 Filed Jul 3, 2018 16:43 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 22,756 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001104659-18-043863 · a4.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,756 Underlying: Common Stock · 22,756 shares Expires 2028-07-02 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which began on June 20, 2018. Read SEC document |
| June 22, 2018 Filed Jun 25, 2018 21:03 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $4.91 | $0.00 |
DisclosureSEC source: 0001193805-18-000906 · e618131_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2028-06-22 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 22, 2028 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| July 03, 2017 Filed Jul 5, 2017 17:59 UTC | Neos Therapeutics, Inc. NEOS · Entity 141061 | GrantStock Option (Right to Buy) · Derivative | 18,322 | $0.00 Strike: $7.65 | $0.00 |
DisclosureSEC source: 0001104659-17-043629 · a4.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,322 Underlying: Common Stock · 18,322 shares Expires 2027-07-03 F1 · derivative.exercise_date: This stock option vests in equal quarterly installments over a one-year period which begins on June 15, 2017. Read SEC document |
| June 06, 2017 Filed Jun 8, 2017 22:00 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 53,837 | $0.00 Strike: $3.66 | $0.00 |
DisclosureSEC source: 0001193805-17-001053 · e616260_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,837 Underlying: Common Stock · 53,837 shares Expires 2027-06-06 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) June 6, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
| February 14, 2017 Filed Feb 17, 2017 01:13 UTC | ADMA BIOLOGICS, INC. ADMA · Entity 4477 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001193805-17-000278 · e615796_4-fong.xml · derivative · entry 1 Fong Bryant · CIK 0001542298 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-02-14 F1 · derivative.exercise_date: The option vests in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. F2 · derivative.expiration_date: The option terminates on the earlier of (i) February 14, 2027 and (ii) the one year anniversary of the reporting person's ceasing to serve as a director of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.